Scholar Rock News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.11.24	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga)
12.11.24	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Businesswire)
04.11.24	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Businesswire)
01.11.24	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Businesswire)
31.10.24	Scholar Rock to Participate in Upcoming Investor Conferences (Businesswire)
31.10.24	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Businesswire)
22.10.24	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Businesswire)
09.10.24	Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis (RTTNews)
09.10.24	Here's Why Everybody's Talking About Scholar Rock Right Now (MotleyFool)
09.10.24	Scholar Rock Prices Upsized $300 Mln Public Offering Of Common Stock And Pre-Funded Warrants (RTTNews)
09.10.24	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
07.10.24	Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
07.10.24	How Is The Market Feeling About Scholar Rock Holding? (Benzinga)
07.10.24	Scholar Rock's Phase 3 SAPPHIRE Study Of Apitegromab In SMA Meets Primary Goal; Stock Surges (RTTNews)
07.10.24	Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) (Businesswire)
10.09.24	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Businesswire)
04.09.24	Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer (Businesswire)
29.08.24	Scholar Rock to Participate in Upcoming Investor Conferences (Businesswire)
08.08.24	Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress (Businesswire)
23.07.24	Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Businesswire)
22.05.24	Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity (Businesswire)
20.05.24	Scholar Rock to Participate in Upcoming Investor Conferences (Businesswire)
14.05.24	Scholar Rock to Host Investor Day on May 22, 2024 (Businesswire)
07.05.24	Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress (Businesswire)
28.03.24	Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst (Benzinga)
19.03.24	Scholar Rock Reports Wider Loss For Full Year (RTTNews)
19.03.24	Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress (Businesswire)
28.02.24	Scholar Rock to Participate in Upcoming Investor Conferences (Businesswire)
15.02.24	Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer (Businesswire)
12.01.24	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.01.24	Scholar Rock Provides Corporate Update and Highlights Priorities for 2024 (Businesswire)
19.12.23	Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Businesswire)
07.11.23	Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress (Businesswire)
02.11.23	Scholar Rock to Participate in Upcoming Investor Conferences (Businesswire)
23.10.23	Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (Businesswire)
16.10.23	Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Businesswire)
12.10.23	Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock (Businesswire)
11.10.23	Scholar Rock Announces Proposed Public Offering of Common Stock (Businesswire)
11.10.23	Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders (Businesswire)
09.08.23	Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress (Businesswire)
30.06.23	New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy (Businesswire)
01.06.23	Scholar Rock to Present at the Jefferies Healthcare Conference (Businesswire)
09.05.23	Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress (Businesswire)
10.04.23	Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors (Businesswire)
07.03.23	Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress (Businesswire)
27.02.23	Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference (Businesswire)
09.01.23	Scholar Rock Provides Corporate Update and Highlights Priorities for 2023 (Businesswire)
03.01.23	Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
15.11.22	Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.10	1.25 %	K V
Part Grp Hldg	1’279.00	1.03 %	K V
UBS Group	28.35	0.96 %	K V
Lonza Grp	523.60	0.61 %	K V
CieFinRichemont	121.80	0.50 %	K V
Swiss Re	129.55	-0.38 %	K V
Swiss Life Hldg	718.80	-0.39 %	K V
Swisscom	507.00	-0.59 %	K V
Novartis	92.80	-0.62 %	K V
Nestle	76.06	-0.76 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Scholar Rock Holding Corporation Registered shs

Aktien Top/Flop

Meistgelesene Nachrichten